Wyeth Indux
Executive Summary
Approval of long bone fracture healing indication for recombinant bone morphogenic protein expected by early 2002, American Home Products CEO Robert Essner tells analysts May 16. Indux (BMP-2) is in Phase III for three indications: long bone fracture, spinal fusion (with Medtronic/Sofamor Danek) and dental craniofacial use. In Phase III trials, standard care of a tibia fracture healed in 20 weeks, while standard care with Indux healed in 14 weeks with more complete bone fusion. Indux sales are expected to reach $500 mil. by 2004, Essner says